2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology

Seattle, WA US
April 28, 2023 to April 30, 2023

This annual oncology conference, 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology (SCHD23), will feature lectures, panel discussions and debates among leaders across the spectrum of cancer care delivery. This conference will bring together oncology professionals, cancer disparity researchers, and other stakeholders to discuss the factors leading to cancer health disparities and ways to overcome the impact of these factors to optimize outcomes of cancer patients.

SCHD23 is an accredited continuing education activity (CME activity) that will foster collaborative interdisciplinary interactions and partnerships to stimulate the development of new research and clinical practices that reduce cancer health disparities and improve outcomes of the diverse patient population.

Target Audience

  • Oncologist and Hematologists
  • Oncology and Hematology Nurse Practitioners
  • Oncology and Hematology Physician Assistants
  • Oncology and Hematology Nurses
  • Oncology and Hematology Pharmacists
  • Oncology and Hematology Fellows/Residents
  • Oncology and Hematology Researchers
  • Others interested in cancer disparities

HOTEL RESERVATION

A limited number of rooms have been reserved at the Grand Hyatt Seattle for participants of the 2023 Summit on Cancer Health Disparities (SCHD23). Please reserve your room by Friday, April 7, 2023, for the discounted rate listed below.

Link to book your hotel room  - https://www.hyatt.com/en-US/group-booking/SEAGH/G-SCHD

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Identify drivers of cancer health disparities and review their impact on patients along the cancer continuum.
  • State the financial and physical barriers and review strategies to navigate these factors to optimize the management of patients with cancer.
  • Incorporate evidence-based strategies to minimize the impact of specific drivers of inequity in the management of patients with cancer.
  • Review barriers to using precision-guided cancer care and discuss evidence-based strategies to navigate these barriers to incorporate the new standards of care in managing patients with cancer.
  • Describe challenges and develop novel approaches to improve the participation of underrepresented communities in clinical trials.
Course summary
Available credit: 
  • 16.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 16.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 16.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 16.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 16.00 Contact Hours.
Course opens: 
10/01/2022
Course expires: 
06/15/2023
Event starts: 
04/28/2023 - 7:52am PDT
Event ends: 
04/30/2023 - 4:00pm PDT
Cost:
$450.00

Day 1 - April 28, 2023

07:00 AM - 08:30 AM          REGISTRATION, BREAKFAST & EXHIBITS


08:30 AM - 09:30 AM           SESSION 1 - Clinical trials

Chair: Dr. Hala Borno

08:30 AM - 08:45 AM          Rising tide of biomarker selected studies - how genomic testing is key to unlocking inequities in oncology clinical trial access - Dr. Hiba Khan

08:45 AM - 09:00 AM          Advanced imaging and stage migration - how finding more diseases may lead to more opportunities - Dr. Curtiland Deville

09:00 AM - 09:15 AM          Applying a social determinant of health framework to address clinical trial inequities - Dr. Samuel Washington

09:15 AM - 09:30 AM          Q&A/Panel


09:30 AM - 10:30 AM          SESSION 2 - Immunotherapy and cellular therapy

Chair: Dr. Shailender Bhatia

09:30 AM - 09:45 AM          The tsunami of cellular immunotherapies is coming: How can we prepare for equitable access? - Dr. Rahul Banerjee

09:45 AM - 10:00 AM          Immune checkpoint inhibitors: Innovative dosing strategies to expand access globally - Dr. Lisa Tachiki

10:00 AM - 10:30 AM          Q&A/Panel - Session speakers + Dr. Krishna Komanduri, Dr. Hiba Khan


10:30 AM - 11:00 AM          BREAKS & EXHIBITS


11:00 AM - 12:00 PM          SESSION 3 - Novel therapies in cancer

Chair: Dr. Mark Pegram 

11:00 AM - 11:30 AM          Keynote lecture - Dr. Jerry Radich

11:30 AM - 12:00 PM          Panel discussion/Q&A  - Dr. Parameswaran Hari, Dr. Lidia Schapira, & Dr. Manali Patel


12:00 PM - 01:00 PM          LUNCH & EXHIBITS


01:00 PM - 02:30 PM          SESSION 4 - Access to Cancer Care in LMIC - Navigating Current Challenges

Chair: Dr. Aparna Parikh 

01:00 PM - 01:20 PM          Oncology Nurse Capacity Building Program in a Low-Income Country Setting  - Lori Buswell, MSN, ANP-C & Olivier Habimana, RN

01:20 PM - 01:35 PM          The Nursing Experience in Botswana: Leading Patient-Centered Care - Lorraine Drapek, DNP, FNP-BC, AOCNP

01:35 PM - 01:45 PM          Panel/Q&A 

01:45 PM - 02:00 PM          Equitable Partnerships in Global Oncology: Best Practice Examples of a AMCs/LMICs partnership - Dr. Katherine Van Loon

02:00 PM - 02:15 PM          Equitable Partnerships in Global Oncology: Best Practice Examples of a AMCs/LMICs partnership - Dr. Erika Ruiz-Garcia

02:15 PM - 02:30 PM          Panel/Q&A


02:30 PM - 04:00 PM          SESSION 5 - Addressing Disparities in Diagnostics, Artificial Intelligence & Machine Learning

Chair: Dr. Ronald Balassanian & Dr. Dan Milner

02:30 PM - 02:45 PM          See, Test & Treat Programs in Domestic Setting - Dr. Eva M. Wojcik

02:45 PM - 03:00 PM          Breast fine needle aspiration (FNA) biopsy in battling diagnostic barriers to cancer care - Dr. Asteria Kimambo

03:00 PM - 03:15 PM          Applied machine learning to improve communication and end-of-life care for patients with cancer - Dr. Christopher Manz

03:15 PM - 03:30 PM          Making a smarter oncology clinic: how can artificial intelligence identify and reduce disparities in care? - Dr. Julian Hong

03:30 PM - 04:00 PM          Panel discussion - Dr. Wojcik, Dr. Kimambo, Dr. Manz, Dr. Hong, Dr. Milner, & Dr. Ronald Balassanian


04:00 PM - 05:00 PM           Career in Oncology - Success Lounge

Chair: Dr. Michael Schweizer & Dr. Jerry Radich

04:00 PM - 04:10 PM          Academic career - Dr. Katherine Van Loon

04:10 PM - 04:20 PM          Community practice - Dr. Tanya Wahl

04:20 PM - 04:30 PM          Disparities in cancer care - Dr. Narjust Florez

04:30 PM - 05:00 PM          Panel discussion - Dr. Andrea Veatch

 

Day 2 - April 29, 2023

07:00 AM - 08:00 AM          REGISTRATION, BREAKFAST & EXHIBITS


08:00 AM - 09:00 AM          SESSION 6 - LGBTQI, Young Adults 

Chair: Dr. David Aboulafia

08:00 AM - 08:15 AM          Supportive care among people living with HIV and cancer in the US - Dr. Jessica Islam

08:15 AM - 08:30 AM          Engaging LGBTQI+ communities in clinical trials - Michael Louella, BS

08:30 AM - 08:45 AM          Engaging resource-constrained countries in research trials of HIV and Cancer: Lessons from Uganda and the AIDS Malignancy Consortium - Dr. Warren Phipps

08:45 AM - 09:00 AM          Panel/Q&A 


09:00 AM - 10:00 AM          SESSION 7 - Plenary session

Chairs: Dr. Hannah Linden & Dr. Ana Maria Lopez

09:00 AM - 09:30 AM          Precision Medicine in Low and Middle-Income Countries - Dr. Julie Gralow

09:30 AM - 10:00 AM          Panel/Q&A - LaToya Williams, MBA, Dr. Katherine Van Loon, Dr. Marianne Dubard-Gault


10:00 AM - 10:15 AM          BREAKS & EXHIBITS


10:15 AM - 11:15 AM          SESSION 8 - Surgical Oncology

Chair: Dr. Evan Glazer

10:15 AM - 10:30 AM          Understanding disparities in palliative care of the cancer surgery patient - Dr. Bridget Fahy

10:30 AM - 10:45 AM          Identifying opportunities to address disparities in gastrointestinal surgical oncology - Dr. Ambria Moten

10:45 AM - 11:00 AM          Rural/urban disparities in peri-operative systemic therapy in patients with breast and cutaneous malignancies - Dr. Cristina O'Donoghue

11:00 AM - 11:15 AM          Panel/Q&A


11:15 AM - 12:15 PM          SESSION 9 - Radiation Oncology

Chair: Dr. Lia Moriguchi Halasz

11:15 AM - 11:30 AM          Cancer Equity Research: Priorities for a New Era - Dr. Gita Suneja 

11:30 AM - 11:40 AM          Disparities in Access to Radiation Oncology Facilities by Race and Ethnicity in Washington State and United States - Dr. Solmaz Amiri 

11:40 AM - 11:50 AM          Cancer Equity Globally: the Radiation Oncology Perspective - Dr. Benjamin Li

11:50 AM - 12:00 PM          Global Expertise in Medical Physics - Dr. Afua Yorke 

12:00 PM - 12:15 PM          Question and Answer for all speakers


12:30 PM - 01:30 PM          LUNCH & EXHIBITS


01:30 PM - 02:45 PM          SESSION 10 - Private practice and academia

Chair: Dr. Ulka Vaishampayan

01:30 PM - 02:00 PM          Improving Access: A Veterans Health System Perspective - Dr. Julie Graff

02:00 PM - 02:30 PM          The Access and Quality of Palliative Care within Cancer Care Community - Dr. Ishwaria Subbiah

02:30 PM - 02:45 PM          Panel discussion: Improving Cancer Care in the Academia and Community: Working Together towards a common goal! - Dr. Joseph Rosales, Dr. Julie Graff, Dr. Paul Monk, Dr. Ishwaria Subbiah, & Dr. Scott Tykodi


02:45 PM - 03:45 PM          SESSION 11 - Career in Cancer Health Disparities - training and funding opportunities

Chair: Dr. Ana Maria Lopez

02:45 PM - 02:50 PM          Welcome and introduction - Dr. Ana Maria Lopez

02:50 PM - 03:20 PM          Keynote lecture - Dr. Nelson Aguila

03:20 PM - 03:45 PM          Panel discussion - Dr. Nelson Aguila, Anna Marsden, MBA, Reuben Cano, & Dr. Candace Chow


03:45 PM - 04:45 PM          SESSION 12 - Current oncology workforce (Avoiding burnout, optimizing patient care)

Chair: Dr. Hannah Linden

03:45 PM - 04:10 PM          What’s Moral Distress got to do with it? Equity and Burnout - Dr. Claudia Finkelstein

04:10 PM - 04:45 PM          Panel/Q&A- Dr. Natalie Uy & Dr. Lynn Symonds


06:00 PM - 09:00 PM          Binaytara Foundation Annual Gala

 

Day 3 - April 30, 2023

07:00 AM - 08:00 AM          REGISTRATION, BREAKFAST & EXHIBITS


08:00 AM - 08:30 AM          Career Reflection - Dr. Edith Mitchell

08:30 AM - 09:10 AM          Oral Abstracts - This is a non-CME session

Chair: Dr. Siddhartha Yadav

08:30 AM - 08:38 AM          A Mixed Methods Study to Examine the Influence of structural racism on Treatment in aggressive hematologic malignancies- Ana Maria Avila and Presented by Jerry Luo, MD, DO

08:38 AM - 08:46 AM          Temporal trend in the use of medical interpreters for gastric cancer patients: a single-institution study- April Choi, MD

08:46 AM - 08:54 AM          Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients- Daniela Urueta Portillo, MD

08:54 AM - 09:02 AM          Social disparities leading to non-adherence in women with abnormal cervical cancer screening- Kaitlyn Estes

09:02 AM - 09:10 AM          Understanding Improvements in Disparities in Breast Cancer Care in Memphis, Tennessee: A Comparison of Two Time Cohorts- Linnea Cripe, MD


09:10 AM - 10:15 AM          Poster Abstracts and Break 


10:15 AM - 12:00 PM          SESSION 13 - Screening and Early detection

Chair: Dr. Robert Smith

10:15 AM - 10:35 AM          Examining Implicit Bias and Health Disparities through the Cancer Screening Lens - Dr. Shana O. Ntiri

10:35 AM - 10:55 AM          The use of prediction models to reduce racial disparities in lung cancer Screening eligibility - Dr. Rebecca Landy

10:55 AM - 11:15 AM          Computable Practice Guidelines and Clinical Decision Support Can Help Address Health Disparities in Cervical Cancer Screening and Management - Ginny Meadows, MSHI, RN-BC

11:15 AM - 11:35 AM          Applying precision approaches to address disparities in follow-up colonoscopy uptake - Dr. Gloria Coronado

11:35 AM - 12:00 PM          Panel/Q&A


12:00 PM                            Adjourn

Grand Hyatt Seattle
721 Pine St
Seattle, WA 98101
United States

HOTEL RESERVATION

A limited number of rooms have been reserved at the Grand Hyatt Seattle for participants of the 2023 Summit on Cancer Health Disparities (SCHD23). Please reserve your room by Friday, April 7, 2023, for the discounted rate listed below.

Link to book your hotel room  - https://www.hyatt.com/en-US/group-booking/SEAGH/G-SCHD

NO SHOW POLICY:

In the event that a guest does not check into their room on the first night of their reservation, this will be considered a “no show”. Client understands that a no show room is released at midnight for all remaining days of the reservation. Reinstatement of the reservation will be based on hotel availability and cannot be guaranteed. All no shows will be charged a fee of one night’s room and tax to the method of payment used to guarantee the reservation (individual credit card or group master account).

CANCELLATION

All individual reservations must be guaranteed by credit card when making the reservation. To avoid cancellation fees, guestsmay cancel their reservation by 4pm PST 24 hours prior to their arrival. Guaranteed reservations not cancelled within the 24 hours prior to arrival will be billed to the guest or Group, as appropriate.

PARKING

Course Director(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Hannah Linden, MD FACP

has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Grant Or Contract) with Veru Pharmaceuticals;.
has a financial relationship (Professional Services) with Gillead ;.
has a financial relationship (Grant Or Contract) with Tolmar;.
has a financial relationship (Grant Or Contract) with GE Healthcare ;.

Ana Maria Lopez, MD, MPH

has no relevant financial relationships to disclose at this time.

Aparna Parikh, MD

has a financial relationship (Other) with Eli Lilly ;.
has a financial relationship (Other) with Checkmate Pharmaceuticals;.
has a financial relationship (Other) with Roche;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Other) with Roche;.
has a financial relationship (Other) with Natera;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Grant Or Contract) with Plexxicon;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Other) with Pfizer ;.
has a financial relationship (Other) with Biofidelity;.
has a financial relationship (Other) with Guardant;.
has a financial relationship (Grant Or Contract) with PMV Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Mirati;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Other) with C2i genomics;.
has a financial relationship (Other) with Inivata;.
has a financial relationship (Other) with FMI;.
has a financial relationship (Grant Or Contract) with PureTech;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Natera;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

H. Aguila, Doctor of Veterinary Medicine

has no relevant financial relationships to disclose at this time.

Solmaz Amiri, DDes, Msc

has no relevant financial relationships to disclose at this time.

Linda Armstrong, Panel Speaker

has a financial relationship (Employment) with Novartis;.
has a financial relationship (Professional Services) with iBio Inc;.
has a financial relationship (Professional Services) with Upstream Bio;.

Rahul Banerjee, MD, FACP

has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Guidepoint Global;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.

Lori Buswell, MSN, ANP-C

has no relevant financial relationships to disclose at this time.

Reuben Ryan Cano

has no relevant financial relationships to disclose at this time.

Candace Chow, PhD

has no relevant financial relationships to disclose at this time.

Gloria Coronado, PhD

has a financial relationship (Professional Services) with Exact Sciences;.
has a financial relationship (Grant Or Contract) with Guardant Health;.

Curtiland Deville, MD

has no relevant financial relationships to disclose at this time.

Lorraine Drapek, DNP FNP-BC AOCNP

has no relevant financial relationships to disclose at this time.

Marianne Dubard-Gault, MD, MS

has no relevant financial relationships to disclose at this time.

Bridget Fahy

has a financial relationship (Stock) with Repligen Corp;.
has a financial relationship (Stock) with Moderna;.
has a financial relationship (Stock) with Guardant Health, inc;.
has a financial relationship (Stock) with HCA Healthcare, Inc;.
has a financial relationship (Stock) with Editas Medicine, Inc;.
has a financial relationship (Stock) with Masimo Corp;.
has a financial relationship (Stock) with Globus Medical, Inc;.
has a financial relationship (Stock) with Teladoc Health Inc;.
has a financial relationship (Stock) with Intuitive Surgical, Inc;.
has a financial relationship (Stock) with Biogen, Inc;.
has a financial relationship (Stock) with Bristol-Myers Squibb, Co;.
has a financial relationship (Stock) with ResMed Inc;.
has a financial relationship (Stock) with Seagen, Inc;.
has a financial relationship (Stock) with Neurocrine Biosciences;.
has a financial relationship (Stock) with GoodRx Holdings Inc;.
has a financial relationship (Stock) with Shockwave Medical, Inc;.
has a financial relationship (Stock) with Veeva Systems Inc;.
has a financial relationship (Stock) with STAAR Surgical Co;.
has a financial relationship (Stock) with Fulgent Genetics, Inc;.
has a financial relationship (Stock) with DexCom, Inc;.
has a financial relationship (Stock) with Align Technology, Inc;.
has a financial relationship (Stock) with United Health Group;.

Claudia Finkelstein, MDCM

has no relevant financial relationships to disclose at this time.

Narjust Florez, Associate Director of Cancer Care Equity Program, Thoracic Medical Oncologist

has a financial relationship (Professional Services) with DSI;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Astrazeneca;.
has a financial relationship (Professional Services) with Neogenomics;.

Julie Graff, MD

has no relevant financial relationships to disclose at this time.

Julie Gralow, MD

has no relevant financial relationships to disclose at this time.

Olivier Habimana, RN, BScN

has no relevant financial relationships to disclose at this time.

PARAMESWARAN HARI, MD

has a financial relationship (Employment) with Iovance Biotherapeutics;.

Julian Hong

has no relevant financial relationships to disclose at this time.

Jessica Islam, PhD, MPH

has no relevant financial relationships to disclose at this time.

Hiba Khan, MD, MPH

has no relevant financial relationships to disclose at this time.

Asteria Kimambo, MD, MMED, Anatomical Pathologist

has no relevant financial relationships to disclose at this time.

Krishna Komanduri, MD

has a financial relationship (Independent contractor) with Iovance;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Cargo Therapeutics;.
has a financial relationship (Independent contractor) with CRISPR Therapeutics;.
has a financial relationship (Independent contractor) with Roche;.
has a financial relationship (Independent contractor) with Avacta Therapeutics;.
has a financial relationship (Independent contractor) with Optum Health;.
has a financial relationship (Independent contractor) with Incyte;.

Rebecca Landy, PhD

has no relevant financial relationships to disclose at this time.

Benjamin Li, MD, MBA

has no relevant financial relationships to disclose at this time.

Michael Louella, BS

has no relevant financial relationships to disclose at this time.

Christopher Manz, MD MSHP

has no relevant financial relationships to disclose at this time.

Anna Marsden

has no relevant financial relationships to disclose at this time.

Ginny Meadows, MSHI, RN-BC

has no relevant financial relationships to disclose at this time.

Edith Mitchell, MD, MACP, FCCP, FRCP

has a financial relationship (Professional Services) with SEMA4;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Bristol, Myers, Squibb;.
has a financial relationship (Professional Services) with Corvus;.
has a financial relationship (Employment) with Thomas Jefferson University;.
has a financial relationship (Professional Services) with Astellas;.
has a financial relationship (Grant Or Contract) with Sanofi;.

Paul Monk

has no relevant financial relationships to disclose at this time.

Ambria Moten, MD, MS

has no relevant financial relationships to disclose at this time.

Shana Ntiri, Shana O. Ntiri, MD, MPH, FAAFP

has no relevant financial relationships to disclose at this time.

Cristina ODonoghue, MD, MPH

has no relevant financial relationships to disclose at this time.

Sydney Osborne

has a financial relationship (Employment) with Seagen Inc. ;.

Manali Patel, MD, MPH, MS, FASCO

has no relevant financial relationships to disclose at this time.

Warren Phipps

has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Erika Ruiz Garcia, MD, MSc

has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with AMGEN;.
has a financial relationship (Other) with ROCHE/Genentech;.
has a financial relationship (Other) with BAYER;.

Lidia Schapira, Professor of Medicine

has a financial relationship (Independent contractor) with Blue Note Therapeutics;.

Ishwaria Subbiah, MD, MS

has no relevant financial relationships to disclose at this time.

Gita Suneja, MD, MSHP

has no relevant financial relationships to disclose at this time.

Lynn Symonds

has no relevant financial relationships to disclose at this time.

Lisa Tachiki, MD

has no relevant financial relationships to disclose at this time.

Scott Tykodi, MD, PhD

has a financial relationship (Grant Or Contract) with Exelixis;.
has a financial relationship (Professional Services) with FirstWord;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with Targeted Oncology;.
has a financial relationship (Grant Or Contract) with AVEO Oncology;.
has a financial relationship (Professional Services) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Pfizer;.

Natalie Uy, MD

has no relevant financial relationships to disclose at this time.

Katherine Van Loon, MD, MPH

has no relevant financial relationships to disclose at this time.

Andrea Veatch, MD

has no relevant financial relationships to disclose at this time.

Tanya Wahl, Medical Oncologist, Medical Director Providence Swedish Cancer Institute Issaquah

has no relevant financial relationships to disclose at this time.

Samuel Washington

has no relevant financial relationships to disclose at this time.

LaToya Williams, MBA

has no relevant financial relationships to disclose at this time.

Eva Wojcik

has no relevant financial relationships to disclose at this time.

Afua Yorke, PhD

has no relevant financial relationships to disclose at this time.
Moderator(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Ron Balassanian, MD

has a financial relationship (Stock) with Cerus corp;.
has a financial relationship (Professional Services) with Genentech;.

Shailender Bhatia, MD

has a financial relationship (Professional Services) with Regeneron/Sanofi;.
has a financial relationship (Grant Or Contract) with 4SC;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Immune Design;.
has a financial relationship (Grant Or Contract) with NantKwest;.
has a financial relationship (Grant Or Contract) with Amphivena;.
has a financial relationship (Grant Or Contract) with Exicure;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.
has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Kuni Foundation;.
has a financial relationship (Grant Or Contract) with Novartis;.

Hala Borno, M.D.

has a financial relationship (Stock) with Trial Library, Inc;.
has a financial relationship (Stock) with Collective Health, Inc;.
has a financial relationship (Stock) with Waymark, Inc;.

Evan Glazer, MD, PhD, FACS, FSSO

has no relevant financial relationships to disclose at this time.

Lia Halasz, MD

has a financial relationship (Grant Or Contract) with Biomimetix;.

Hannah Linden, MD FACP

has a financial relationship (Grant Or Contract) with Veru Pharmaceuticals;.
has a financial relationship (Professional Services) with Gillead ;.
has a financial relationship (Grant Or Contract) with Tolmar;.
has a financial relationship (Grant Or Contract) with GE Healthcare ;.
has a financial relationship (Grant Or Contract) with Sanofi;.

Ana Maria Lopez, MD, MPH

has no relevant financial relationships to disclose at this time.

Danny Milner, Jr, MD, MSc, MBA

has no relevant financial relationships to disclose at this time.

Aparna Parikh, MD

has a financial relationship (Other) with Biofidelity;.
has a financial relationship (Other) with Guardant;.
has a financial relationship (Grant Or Contract) with PMV Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Mirati;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Other) with Pfizer ;.
has a financial relationship (Other) with Inivata;.
has a financial relationship (Other) with FMI;.
has a financial relationship (Grant Or Contract) with PureTech;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Natera;.
has a financial relationship (Other) with C2i genomics;.
has a financial relationship (Other) with Eli Lilly ;.
has a financial relationship (Other) with Checkmate Pharmaceuticals;.
has a financial relationship (Other) with Roche;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Other) with Natera;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Grant Or Contract) with Plexxicon;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Other) with Roche;.

Mark Pegram, MD

has no relevant financial relationships to disclose at this time.

Jerald Radich

has a financial relationship (Other) with Cepheid;.
has a financial relationship (Other) with NuProbe;.
has a financial relationship (Other) with Novartis;.

Michael Schweizer, MD

has a financial relationship (Independent contractor) with Pharmain;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Sanofi;.

Robert Smith, PhD

has no relevant financial relationships to disclose at this time.

Ulka Vaishampayan, MD

has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with sanofi;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Pfizer;.
Planning committee(s)

Hala Borno, M.D.

has a financial relationship (Stock) with Waymark, Inc;.
has a financial relationship (Stock) with Trial Library, Inc;.
has a financial relationship (Stock) with Collective Health, Inc;.

Evan Glazer, MD, PhD, FACS, FSSO

has no relevant financial relationships to disclose at this time.

Ana Maria Lopez, MD, MPH

has no relevant financial relationships to disclose at this time.

Danny Milner, Jr, MD, MSc, MBA

has no relevant financial relationships to disclose at this time.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Umang Swami, MD, MS

has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Seattle Genetics;.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from the following companies:

  • Novocure, Inc. 
  • Exact Sciences
  • Gilead Sciences
  • Pfizer

Available Credit

  • 16.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 16.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 16.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 16.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 16.00 Contact Hours.

 

Price

Cost:
$450.00
Please login or register to take this course.

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you do not plan to claim CME credits, you can register here.

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again. 

CANCELLATION POLICY

Refund Policy 

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post-tests as well as course evaluations.